<DOC>
	<DOCNO>NCT00004757</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine whether acyclovir ( ACV ) oral suspension suppresses recurrent skin lesion improve neurologic outcome neonate localize herpes simplex virus type 2 infection administer 6 month placebo-controlled study . II . Determine whether prevention recurrent skin lesion reduce long-term neurologic morbidity . III . Determine whether resistant disease develop oral ACV therapy . IV . Evaluate natural history recurrent skin lesion . V. Measure adverse effect laboratory abnormality associate long-term oral ACV therapy infant young child .</brief_summary>
	<brief_title>Phase III Randomized , Placebo-Controlled Study Acyclovir Oral Suspension Neonatal Herpes Simplex Virus Infection Limited Skin , Eyes , Mouth</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double-blind study . Patients stratify participate institution . All patient treat intravenous acyclovir 14 day . Patients randomly assign 1 2 treatment group follow criterion meet : systemic disease involvement , document negative cerebrospinal fluid exam , brain computerized tomography , magnetic resonance imaging ; entry criterion continue meet . Randomized treatment begin 8 hour final dose intravenous acyclovir . One group treat oral acyclovir , control group receive oral placebo . Treatment continue 6 month absence unacceptable toxicity , systemic disease , 2 recurrence skin lesion . Patients follow 6 month , yearly least 4 year . The study duration estimate 4 year .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Virologically confirm herpes simplex virus type 2 ( HSV2 ) skin lesion localize skin , eye , mouth No central nervous system disseminate disease Normal cerebrospinal fluid WBC le 20 Protein less 90 mg/dL Normal brain computerize tomography magnetic resonance imaging ( MRI ) MRI feasible No HSV1 Patient Characteristics Age : Under 29 day Renal : Creatinine great 1.5 mg/dL Other : Birth weight least 1200 g Gestational age great 32 week No breast feed mother acyclovir</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>29 Days</maximum_age>
	<verification_date>January 1998</verification_date>
	<keyword>herpes simplex virus infection</keyword>
	<keyword>herpesvirus infection</keyword>
	<keyword>immunologic disorder infectious disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>viral infection</keyword>
</DOC>